← All Mei Pharma, INC filings

Mei Pharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MEIP
Mei Pharma, INC
10-K: Lite Strategy Pivots to Digital Assets Amidst Pharma Development Challenges
Lite Strategy, Inc. (LITS) reports a significant net loss for FY2026, detailing a strategic shift from oncology drug development to a primary reserve asset strategy focused on Litecoin (LTC), alongside ongoing pre-clinical work in non-oncologic indications.
NASDAQ
MEIP
Mei Pharma, INC
10-K: Lite Strategy Pivots to Litecoin Treasury, Exits Pharma
Lite Strategy, Inc., formerly MEI Pharma, has completed a $100 million PIPE and fully deployed proceeds into a Litecoin Treasury Strategy, marking a significant shift from its pharmaceutical development focus.
NASDAQ
MEIP
Mei Pharma, INC
10-K: MEI Pharma Explores Strategic Alternatives, Halts Voruciclib Development
MEI Pharma is evaluating strategic options, including a potential wind-down, after discontinuing the clinical development of voruciclib.